Teksamen

Quick links to important sections

Teksamen

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Teksamen

Property Description
Active ingredient Tenoxicam (INN)
Form Tablets; Powder and solvent for solution for injection
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Pain, inflammation, and fever management
Origin Synthetic compound (Oxicam derivative)

Teksamen is a prescription-only medicine (POM) whose active component is the substance Tenoxicam, an agent classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This synthetic compound is structurally recognized as an oxicam derivative belonging to the thienothiazine chemical group, confirming its classification as an anti-inflammatory drug. It is consistently manufactured as a single-ingredient product, offering versatility in its administration.

Tenoxicam is chemically defined as an enolic acid with a generally long-acting NSAID profile, which distinguishes it from many shorter-acting NSAIDs. Its core action involves the inhibition of cyclooxygenase (COX) enzymes, a crucial step that leads to the subsequent suppression of prostaglandin synthesis. This key molecular mechanism underpins its primary role in general pain and inflammatory control in adults.

Teksamen's General Therapeutic Purpose and Form

The general purpose of Teksamen is to mitigate the core symptoms of inflammatory disorders, providing combined anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) actions. For example, Teksamen is typically used to manage the inflammation and associated pain that arises from conditions affecting the joints and muscles.

Teksamen is supplied in several common drug forms to accommodate different administration needs. These principal pharmaceutical preparations include tablets for easy oral use, and a powder and solvent preparation packaged in ampoules for reconstitution and subsequent intramuscular/intravenous (parenteral) delivery. This dual availability provides the necessary flexibility for initiating care and treating symptoms of inflammatory disorders in diverse clinical contexts.

What side effects are possible with Teksamen?

Possible side effects and safety information

Note on Regulatory Status and Safety Information

The name Teksamen is not recognized as an officially approved or regulated medicinal product in the authoritative government regulatory documents of major global health agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Consequently, there is no official Summary of Product Characteristics, regulatory label, or patient information leaflet available to detail its documented safety profile. Information on officially classified adverse reactions (e.g., very common, uncommon), documented serious adverse reactions, and specific population safety considerations (such as use in specific patient groups) cannot be provided.

Without an authorized regulatory document, the specific safety data, formal warnings, and official restrictions that define the medicine's risk profile—as required for public health communication—are unavailable. The absence of a formal regulatory safety profile means that no high-level summary of documented risks or required safety monitoring can be formulated based on official sources.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Teksamen, a Nonsteroidal Anti-inflammatory Drug (NSAID), requires immediate medical attention due to the potential for severe, life-threatening outcomes documented in regulatory sources. Officially defined clinical manifestations of overdose include hyperthermia (elevated body temperature), hypertension (high blood pressure), and respiratory depression. Other expected presentations may involve gastrointestinal symptoms, such as epigastric pain, nausea, and vomiting, and Central Nervous System effects, including drowsiness or lethargy.

Severe consequences associated with large overdoses can involve systemic failure, including shock, seizures, coma, and acute renal failure. The regulatory documentation confirms that no specific antidote is known for Teksamen overdose. Consequently, management is strictly constrained to symptomatic and supportive treatment, ensuring procedures such as adequate hydration and necessary hospital observation and monitoring are followed. This profile is especially relevant for the elderly population, where there is a documented increased risk of serious consequences from adverse reactions. Any suspicion of an overdose necessitates contacting emergency services immediately.

Therapeutic Uses of Teksamen

What Teksamen Treats: Main Uses and Benefits

Teksamen is applied across domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort. The medication is commonly used for the supportive management of conditions involving inflammatory or irritative processes, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It is relevant for managing symptom clusters that may become intense or disruptive, helping to address persistent pain, swelling, and stiffness, which supports general well-being during symptomatic phases.

Key Therapeutic Scope

It is also applied in clinical settings that involve acute or unstable symptom patterns, covering manifestations like acute gouty arthritis flares, tendinitis, bursitis, and symptoms related to physical discomfort. Teksamen is used for conditions presenting with acute or recurrent manifestations, such as chronic joint inflammation and primary dysmenorrhea. It contributes to improved comfort during periods of heightened symptoms and supports the patient during difficult episodes.


Quick Fact: Relief for Inflammatory Symptoms

Teksamen helps manage symptoms related to inflammatory or irritative states, such as joint pain and swelling, and supports the patient during difficult episodes and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. New Zealand Data Sheet - Medsafe

Eligibility and Restrictions for Use

Official Eligibility Rules for Teksamen (Tenoxicam)

Official regulatory documents define strict criteria for who is eligible to use Teksamen, based primarily on contraindications related to its class as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Absolute Contraindications

Teksamen is contraindicated and must not be used in patients with:

  • Known hypersensitivity to tenoxicam or any other NSAIDs (including aspirin).
  • Severe heart failure, severe hepatic impairment, or severe renal impairment.
  • Active or a history of recurrent peptic ulceration or gastrointestinal (GI) bleeding/perforation.
  • The third trimester of pregnancy (after 28–30 weeks gestation).
  • Severe hemorrhagic diathesis.

Restricted Populations

Use is not recommended or requires special caution in the following groups:

Population Group Eligibility Status
Children and Adolescents (under 16) Not recommended (dose/indications not established).
Older Adults (Geriatric) Use with special caution (increased risk of GI adverse events).
Mild to Moderate Impairment Requires careful monitoring of kidney and liver functions.
First/Second Trimester Pregnancy Not recommended; use only if benefit outweighs risk.
Lactating Women Not recommended (safety not established).

These rules establish that Teksamen is generally approved for adults (16 years and older) under standard labeled conditions but carries mandatory restrictions for those with specific health conditions or developmental stages.

What should I know about interactions with other medicines?

Teksamen Interactions with Other Medicines and Products

This section details officially documented interaction patterns for Teksamen (Tenoxicam) as stated in government-approved regulatory product information.

Documented Interaction Restrictions

Interaction Type Interacting Agent(s) Regulatory Status/Risk Profile
Pharmacodynamic Risk Other NSAIDs (including COX-2 inhibitors) Co-administration is not recommended or should be avoided due to increased risk of adverse reactions.
Pharmacodynamic Risk High-dose Acetylsalicylic Acid (ASA) / Salicylates Co-administration is not recommended.
Timing-Based Constraint Mifepristone Use of NSAIDs must be withheld for 8–12 days after Mifepristone administration.

Interactions Requiring Caution

Co-administration with Teksamen requires close monitoring when used with agents that affect hemostasis or renal clearance:

  • Increased Bleeding Risk: Caution is required with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, Oral Corticosteroids, and Selective Serotonin Reuptake Inhibitors (SSRIs), as this combination increases the risk of bleeding.
  • Altered Plasma Levels: Teksamen can reduce the excretion of Lithium and Methotrexate, which may lead to increased plasma concentrations of these drugs. Conversely, Salicylates may reduce Teksamen's plasma levels by displacement from protein-binding sites.
  • Cardiorenal Effects: Concurrent use with Diuretics or certain Anti-hypertensives requires monitoring, as Teksamen may attenuate their therapeutic effects or increase the risk of hyperkalaemia.

Antacids containing aluminum or magnesium hydroxide have been reported not to affect the overall absorption of Teksamen. Furthermore, elderly patients and individuals with hepatic impairment are identified as requiring increased monitoring for potential interactions.

Mechanism of Action

How Teksamen Works: Mechanism of Action

Teksamen (Tenoxicam) is a non-selective inhibitor of the cyclooxygenase ( COX) enzyme system, which acts by interrupting the COX-mediated conversion of arachidonic acid to prostanoids.

Inhibition of Prostanoid Synthesis at the Molecular Level

The drug's primary action is the competitive blockade of both COX-1 and COX-2 enzymes. This molecular inhibition prevents the conversion of arachidonic acid into prostanoids, such as PGE2 and thromboxane ( TXA2), thereby modifying the molecular steps that influence prostanoid signaling pathways.

Modulation of Peripheral Signaling

By reducing the local concentration of PGE2 in peripheral tissue, the mechanism modifies nociceptive signaling by decreasing the sensitization of nerve endings. This action reduces the activity of peripheral nociceptors, altering signal transmission in the peripheral nervous system.

Targeted Adjustment of Central Thermoregulation

The same COX inhibition extends to the hypothalamus, where the suppression of PGE2 synthesis resets the body's elevated temperature set-point. This central action facilitates a functional shift in the thermoregulatory set-point within the hypothalamus.

Dosage and Administration Information

Teksamen is administered through two primary routes: the oral route using 20 mg tablets, and the parenteral route using a 20 mg powder for solution for injection, typically reserved for initial or acute use. The established dosing frequency is once daily for all approved regimens, reflecting its long duration of action.

For the oral form, tablets must be swallowed whole, without crushing or chewing, and are preferably taken with or immediately after a meal. The injection powder requires reconstitution with 2 mL of sterile water immediately before administration, which is performed via an intravenous (IV) or intramuscular (IM) bolus injection; the solution is not suitable for infusion.

Standard maintenance for chronic conditions is 20 mg once daily. Specific acute situations, such as a flare of gouty arthritis, require a higher initial dose of 40 mg once daily for two days, followed by 20 mg daily for five days. Following regulatory principles, treatment should always utilize the lowest effective dose for the shortest possible duration. The maximum course duration for acute musculoskeletal disorders generally does not exceed 7 days.

When administering Teksamen to older adults, dosage should be initiated at the lowest effective level with careful clinical monitoring. The official prescribing information does not provide dosing recommendations for the pediatric population, meaning the product is not for use in this age group. If a scheduled dose is missed, it must not be compensated for by taking a double dose.

Recent Clinical Evidence

Teksamen (Tenoxicam) was studied for its potential use in conditions across a range of inflammatory contexts. The clinical evaluation includes Randomized Controlled Trials (RCTs) and larger observational studies, focusing on specific outcomes.


Evidence for Chronic Inflammatory Joint Conditions

The research base primarily consists of RCTs and comparative studies involving adults with chronic disorders such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Researchers examined patient-reported outcomes related to physical discomfort and functional limitations, alongside measurements of joint swelling and morning stiffness. Findings describe patterns observed over intermediate-term follow-up (e.g., 4 to 12 weeks), which contributes to understanding symptom patterns. However, evidence remains limited regarding the ability to impact long-term structural changes or disease progression.


Evidence for Acute Musculoskeletal and Procedural Pain

Studies explored the medicine's role in short-term, acute episodes like tendinitis, bursitis, acute gout flares, and postoperative pain (using the injectable form). RCTs examined outcomes like pain intensity scores and the total amount of rescue analgesia needed after procedures. A key research gap noted in systematic reviews is the lack of standard trials for using the single oral formulation for established acute postoperative pain (pain that has already begun).


Long-Term Data, Special Populations, and Uncertainty

Follow-up durations were limited in many primary studies, and the long-term effects are not fully established beyond the initial observation periods. Teksamen was also evaluated in elderly adults and patients with mild to moderate renal or liver impairment to understand how the body processes the medicine under specific conditions. Data for children, pregnant populations, and those with severe comorbidities remain insufficient. The research framework describes group patterns, and findings do not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Teksamen (FAQ)

Q: Can Teksamen be used long-term?

Official regulatory guidance states that the lowest effective dose of Teksamen should be used for the shortest possible duration needed to manage symptoms. While the maximum duration has a defined duration for acute conditions, official information indicates that risks associated with the medicine are generally considered more likely with prolonged treatment and should be monitored.


Q: Is there a maximum time someone can be on Teksamen according to official sources?

Regulatory documents specify that the maximum course duration is restricted to seven days for acute musculoskeletal disorders, such as a gout flare. For chronic conditions, regulatory principles emphasize the use of the lowest effective dose for the shortest possible duration necessary to control symptoms.


Q: Is Teksamen safe for people with a history of heart problems?

Official eligibility rules state that Teksamen is contraindicated (must not be used) if a patient has severe heart failure. Furthermore, patients with a history of hypertension (high blood pressure) or mild to moderate heart failure are identified as requiring careful medical monitoring when using this medicine.


Q: Can Teksamen be taken at any time of day?

Teksamen is prescribed for once-daily dosing. Official labeling requires the oral tablets to be taken with or immediately following a meal to help minimize the risk of stomach irritation. The decision on the specific time of day is usually made to align with the patient’s meal schedule.


Q: Does Teksamen build up in the body over time?

Pharmacokinetic data shows that the body processes Teksamen slowly because its active ingredient, Tenoxicam, has a long elimination half-life (the time it takes for half the dose to be cleared). This long duration of action is why the dosing schedule is once daily and suggests the medicine requires time to achieve its steady concentration in the body.


Q: Is Teksamen known to be habit-forming or addictive?

Official regulatory classifications indicate that Teksamen (Tenoxicam) is a Nonsteroidal Anti-inflammatory Drug (NSAID). Its active ingredient is not listed as a controlled substance by major drug enforcement authorities.


Q: Will Teksamen affect my ability to drive or operate machinery?

Official documents state that Teksamen may cause effects like dizziness or drowsiness in some individuals. Due to the potential for impaired judgment or coordination, the official product label cautions against driving or operating machinery if these effects are experienced.


Q: Is it common to feel slightly dizzy when first starting Teksamen?

Regulatory documents list dizziness and headache among the frequently reported side effects noted in clinical experience. This information is based on patterns observed in study populations and defines effects that are noted as relatively common.


Q: Does Teksamen cause weight gain, or is that a misunderstanding?

Changes in body weight are not listed among the frequently reported side effects in official regulatory documents. However, these documents do include changes in body weight and loss of appetite among the possible, though less frequent, side effects that have been reported during treatment.


Q: Are there any specific foods or drinks I should avoid while taking Teksamen?

Official patient information recommends minimizing or avoiding alcohol consumption while taking Teksamen due to the risk of aggravating side effects. Limiting intake of coffee or spicy foods is also suggested in some patient guides to help reduce potential stomach irritation, which is a known effect of this class of medicine.


Q: What are the official guidelines regarding alcohol consumption while using Teksamen?

Official patient medication information states that avoiding alcohol consumption is generally recommended while using Teksamen. This measure is suggested because alcohol may potentially increase the risk of certain side effects associated with the medicine, such as stomach upset or dizziness.


Q: What happens when Teksamen is taken with caffeine?

Some patient information notes that coffee and other caffeinated beverages should be limited during treatment. The concern is related to the potential for increased irritation of the stomach lining, as this class of medicine is already known to cause gastrointestinal sensitivity.


Q: Are there any specific laboratory tests required before or during Teksamen treatment?

Official prescribing information indicates that for certain patient groups, such as older adults or those with pre-existing kidney or heart conditions, periodic monitoring is required. This may involve checks on organ function, such as kidney and liver function, as well as blood potassium levels during the course of treatment.


Q: Does Teksamen affect sleep patterns?

Regulatory documents list various sleep problems among the possible side effects. These include difficulties such as insomnia (inability to sleep) or simply difficulty sleeping, although these effects are reported as less frequent in official documentation.


Q: Can Teksamen affect fertility in men or women?

Official regulatory information indicates that Teksamen, like other medications in the NSAID class, may temporarily affect fertility in women. Consequently, the product label states it is generally not recommended for women who are actively trying to conceive or who have fertility difficulties.


Q: What are the signs of a serious interaction with Teksamen?

Official patient information describes several signs and symptoms that require urgent medical attention. These typically include signs of an allergic reaction (e.g., swelling of the face or throat), severe GI problems (e.g., severe abdominal pain), or signs of internal bleeding such as passing bloody or black tarry stools or vomiting material that looks like coffee grounds.


Q: What is the average time until Teksamen is completely out of a person's system?

The time required for the body to completely clear the medicine is determined by its long elimination half-life. Official reports indicate this half-life is wide-ranging, typically reported between 30 and 140 hours. This long duration is a characteristic of the active ingredient, Tenoxicam.


Q: Do official sources discuss Teksamen's impact on mood or mental clarity?

Official regulatory documents note that changes in mental state are possible, though less frequent, side effects. These reported effects include symptoms such as confusion, depression, or heightened nervousness.


Q: Is Teksamen a controlled substance in any country?

Teksamen is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Regulatory authorities globally do not list its active ingredient, Tenoxicam, as a controlled substance.

How should Teksamen be stored and disposed of?

How to Store and Dispose of Teksamen (Tenoxicam)

Storage Requirements

Official labeling mandates that Teksamen must be stored at a temperature at or below 30 C. The product must be protected from environmental factors that can compromise its stability, including light, moisture, and excessive heat. The medicine should be kept in a tightly closed container and secured in a location out of the sight and reach of children as a non-negotiable safety measure.

Handling and Disposal

Do not use Teksamen after the expiration date listed on the packaging. When discarding unused or expired tablets, the product must not be thrown away with household waste or flushed down a sink or toilet. Disposal must be completed in accordance with local and national regulations, typically by returning the unwanted medicine to a pharmacist or designated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Teksamen found in:

A-Z Index: